Published in Vaccine Weekly, October 16th, 2002
"Several studies have suggested a positive correlation between heat shock protein (hsp) expression and tumor immunogenicity," commented Xiang-Yang Wang and colleagues at the Roswell Park Cancer Institute in Buffalo, New York. "Independently, many studies have shown that hsp purified from tumors can be used as a tumor-specific vaccine."
The investigators incorporated the cDNA of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.